With years of experience in developing cannabinoid medicines, Australia-based MGC Pharmaceuticals will now be branching into psychedelic medicine development.
The company is the first in Slovenia to receive permission from The Slovenian Ministry of Health to undergo research with psilocybin.
The permission granted covers the development of analytical methods, research of physical-chemical properties of Psilocybin and development of pharmaceutical forms that would be suitable for administration.
Roby Zomer, Managing Director and CEO of MGC Pharmaceuticals, commented: “We are pleased to have obtained permission from the Slovenian Ministry of Health to undertake pharmaceutical research with psilocybin, which puts the company at the forefront of experimental, pharmaceutical research.
“We are extremely grateful to the Slovenian Health Ministry for enabling us to utilise our research expertise in this area.
“Whilst we continue to focus on our core development pipeline of CimetrA and CannEpil, we look forward to working with other pharmaceutical partners to establish the properties of psilocybin and demonstrate how it could be used to develop medicines to treat people with debilitating conditions.”
The company plans to work with other pharmaceutical businesses to collaborate and provide research capabilities for understanding of the properties of psilocybin.
MGC Pharma has stated that this approval will allow it to take the psychedelic industry one step closer to the pharmaceutical industry by helping to develop and research new medicines based on psilocybin, and for MGC to provide such services to the growing industry of psychedelics.
